[Effect of pyridoxine on the psychopathology and pathochemistry of involutional depressions].
In agreement with the catecholamine hypotheses of affective disorders the main role in the pathogenesis of depressive states is allocated to the central "noradrenergic insufficiency". The author thinks it feasible to use pyridoxine (vit. B6) in the treatment of depressive states, inasmuch as it is involved in the process of catecholamine synthesis as a cofactor of DOPA-decarboxylase. The author examined 48 patients among which 31 were with involutional melancholia and 17 with manic-depressive psychoses, manifesting after 40 years. Along with a positive therapeutical effect there was an increase in the noradrenaline excretion and a drop in the relative adrenaline content.
D000328:Adult; D000368:Aged; D000928:Antidepressive Agents; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000652:urine; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000652:urine; D004837:Epinephrine / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000652:urine; D011736:Pyridoxine / Q000627:therapeutic use*
D000928:Antidepressive Agents; D011736:Pyridoxine; D009638:Norepinephrine; D004837:Epinephrine
Vliianie piridoksina na psikhopatologiiu i patokhimiiu depressil6i involiutsiomogo vozrasta.